HGH (Somatropin) vs CJC-1295 / Ipamorelin

HGH (Somatropin)

Recombinant human growth hormone — the actual hormone itself, not a secretagogue. Powerful for body recomposition, with side effects that scale unmistakably with dose.

Best for

Best when maximal, reliable GH/IGF-1 is the priority and side effects and cost are acceptable.

CJC-1295 / Ipamorelin

The workhorse GH-secretagogue stack: a GHRH analogue paired with a selective ghrelin agonist. GHRH plus GHRP produces more GH per pulse than either alone, with a side-effect profile most people find tolerable for indefinite use.

Best for

Best when you want pulsatile, self-produced GH with fewer side effects and intact feedback.

HGH (Somatropin)

Recombinant somatropin is FDA- and EMA-approved for adult growth hormone deficiency, pediatric short stature, and HIV-associated wasting. The drug itself is well-characterised; the body of clinical literature spans four decades. The off-label use in non-deficient adults for body recomposition and anti-aging is not what the approval covers — that is an extrapolation from on-label pharmacology, supported by smaller trials in healthy older adults (Rudman 1990 is the famous one, and several follow-ups since) but not by a large RCT base in healthy populations.

CJC-1295 / Ipamorelin

GHRH + GHRP synergy is well-documented in short-term human studies going back to the early 2000s — the pulse-amplification effect is real and replicated across multiple research groups. What is limited is long-term safety and body-recomposition outcome data. The 12-week protocols people run are an extrapolation from the acute-pulse pharmacology, not from a body-recomp RCT base. The mechanism is tight; the chronic-use evidence is thinner than the popularity suggests.